Managing Avelumab Side Effects in Patients With Merkel Cell Carcinoma

2 Pogledi
administrator
administrator
07/17/23

Howard L. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, discusses the adverse event profile of avelumab (Bavencio) for patients with Merkel cell carcinoma.

  • Kategorija

Prikaži više

0 Komentari Poredaj po

Nema komentara

Komentari na Facebooku

Sljedeći